STOCK TITAN
  1. Home
  2. Sec-filings
  3. BMRN
  4. [Form 4] BIOMARIN PHARMACEUTICAL INC Insider Trading Activity

BioMarin (BMRN) director gets 7,490 RSUs, holds 21,045 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bodem Barbara W. reported acquisition or exercise transactions in this Form 4 filing.

BioMarin Pharmaceutical Inc. director Barbara W. Bodem received a grant of 7,490 shares of common stock in the form of restricted stock units on June 2, 2026. The award had no purchase price, indicating it was compensation rather than an open-market buy. After this grant, she directly holds 21,045 common shares.

Positive

  • None.

Negative

  • None.
Insider Bodem Barbara W.
Role null
Type Security Shares Price Value
Grant/Award Common Stock 7,490 $0.00 --
Holdings After Transaction: Common Stock — 21,045 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 7,490 shares Restricted stock units granted on June 2, 2026
Price per share $0.00 per share Compensation grant, not open-market purchase
Post-transaction holdings 21,045 shares Total BioMarin common stock held directly after grant
Transaction code A (grant, award, or other acquisition) Non-derivative common stock transaction classification
Restricted stock units financial
"Restricted stock units granted on June 2, 2026. Price not applicable."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Form 4 regulatory
"INSIDER FILING DATA (Form 4): {"issuerName": "BIOMARIN PHARMACEUTICAL INC""
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
non-derivative financial
""transaction_type": "non-derivative""
Grant, award, or other acquisition financial
""transaction_code_description": "Grant, award, or other acquisition""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bodem Barbara W.
(Last)(First)(Middle)
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO STREET
(Street)
SAN RAFAEL CALIFORNIA 94901
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/02/2026A7,490A$0(1)21,045D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Restricted stock units granted on June 2, 2026. Price not applicable.
Remarks:
/s/ Tae Sang Yoo, Attorney-in-Fact06/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BioMarin (BMRN) report for Barbara W. Bodem?

BioMarin reported that director Barbara W. Bodem received a grant of 7,490 restricted stock units on June 2, 2026. These units convert into common stock and were awarded as compensation, not purchased in the open market, according to the Form 4 filing.

How many BioMarin (BMRN) shares does Barbara W. Bodem hold after this grant?

Following the June 2, 2026 grant, Barbara W. Bodem directly holds 21,045 shares of BioMarin common stock. This total reflects the addition of 7,490 restricted stock units recorded in the Form 4, showing her updated ownership position as a company director.

Was cash paid for the BioMarin (BMRN) restricted stock units granted to Barbara W. Bodem?

No cash changed hands for this grant. The Form 4 notes a price per share of $0.00, and the footnote explains these were restricted stock units granted as of June 2, 2026, making them a stock-based compensation award rather than a market purchase.

What does transaction code "A" mean in the BioMarin (BMRN) Form 4 for Barbara W. Bodem?

Transaction code "A" on the Form 4 indicates a grant, award, or other acquisition. For Barbara W. Bodem, it reflects an award of 7,490 restricted stock units, classified as a non-derivative acquisition of common stock as part of her director compensation package.

Are the BioMarin (BMRN) shares held by Barbara W. Bodem direct or indirect ownership?

The Form 4 classifies Barbara W. Bodem’s holdings as direct ownership, indicated by the code "D". After the June 2, 2026 restricted stock unit grant, she directly owns 21,045 shares of BioMarin common stock, with no indirect entities listed in this filing.